YARDLEY, Pa., June 04, 2018 (GLOBE NEWSWIRE) — OptiNose, Inc. (NASDAQ:OPTN), announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) and commenced a proposed underwritten public offering of 4,500,000 shares of its common stock. The offering is expected to consist of 2,250,000 shares to be offered by Optinose and 2,250,000 shares to be offered by certain selling stockholders. In addition, Optinose and the selling stockholders are expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 675,000 shares at the public offering price, less the underwriting discount. Optinose will not receive any proceeds from the sale of shares by the selling stockholders. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
Jefferies and Piper Jaffray will act as the lead joint book-running managers for the offering. BMO Capital Markets and RBC Capital Markets will also act as joint book-running managers for the offering and Cantor will act as sole lead manager. This proposed offering will be made only by means of a prospectus. A copy of the preliminary prospectus may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at 877-821-7388 or by email at Prospectus_Department@Jefferies.com; Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924 or by email at email@example.com; BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, 25th Floor, New York, NY 10036, or by telephone at 800-414-3627 or by email at firstname.lastname@example.org; and RBC Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281-8098 or by telephone at 877-822-4089 or by email at email@example.com.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose has offices in the U.S., the U.K. and Norway.
Optinose Investor Contact